Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Rigel Pharmaceuticals Inc changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 160 | 1 | 163 | +4 |
| Shares | 141.6M | 19.0K | 137.6M | −3.98M (−2.8%) |
| Value | $614.5M | $82.0K | $499.6M | −$114.8M (−18.7%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HealthInvest Partners AB | 1,765,000 | $6.41M | 9.60% |
| Laurion Capital Management LP | 1,125,000 | $4.08M | 0.06% |
| Brandywine Global Investment Management, LLC | 258,115 | $937.0K | 0.01% |
| American Century Companies Inc | 220,263 | $800.0K | 0.00% |
| STRS Ohio | 154,000 | $559.0K | 0.00% |
| Arrowstreet Capital, Limited Partnership | 137,389 | $499.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 128,948 | $468.0K | 0.00% |
| Gsa Capital Partners LLP | 115,036 | $418.0K | 0.04% |
| Marshall Wace, LLP | 69,222 | $251.0K | 0.00% |
| ExodusPoint Capital Management, LP | 25,100 | $91.0K | 0.00% |
| Pictet Asset Management SA | 19,004 | $69.0K | 0.00% |
| Janus Henderson Group PLC | 17,060 | $62.0K | 0.00% |
| Jump Financial, LLC | 16,704 | $61.0K | 0.00% |
| E Fund Management Co., Ltd. | 16,554 | $60.0K | 0.00% |
| O'Shaughnessy Asset Management, LLC | 10,375 | $38.0K | 0.00% |
| Point72 Hong Kong Ltd | 8,039 | $29.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 6,612 | $24.0K | 0.00% |
| Hexagon Capital Partners LLC | 22 | $0 | 0.00% |
Sold out (14)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Driehaus Capital Management LLC | 343,000 | $1.49M |
| Gyon Technologies Capital Management, LP | 264,330 | $1.15M |
| Tudor Investment Corp Et Al | 143,966 | $625.0K |
| Jaffetilchin Investment Partners, LLC | 92,931 | $325.0K |
| XTX Topco Ltd | 36,878 | $160.0K |
| Diversified Trust Co | 33,711 | $146.0K |
| Pinz Capital Management, LP | 30,000 | $130.0K |
| Ergoteles LLC | 26,400 | $115.0K |
| Maven Securities LTD | 25,907 | $112.0K |
| Hancock Whitney Corp | 20,435 | $89.0K |
| Lazard Asset Management LLC | 17,088 | $74.0K |
| Quantbot Technologies LP | 1,200 | $5.00K |
| Advisory Services Network, LLC | 125 | $1.00K |
| American Portfolios Advisors | 36 | $156 |
Not filed for Q3 2021 yet (1)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Pictet Asset Management Ltd | 19,004 | $82.0K |